Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • S113: NATIONAL PEGASPARGASE-MO...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.

Bibliographic Details
Published in:HemaSphere
Main Authors: R. Bassan, S. Chiaretti, I. Della Starza, O. Spinelli, A. Santoro, L. Elia, M. S. De Propris, A. M. Scattolin, F. Paoloni, M. Messina, E. Audisio, L. Marbello, E. Borlenghi, P. Zappasodi, C. Vetro, G. Martinelli, D. Mattei, N. Fracchiolla, M. Bocchia, P. De Fabritiis, M. Bonifacio, A. Candoni, V. Cassibba, P. Di Bartolomeo, G. Latte, S. Trappolini, A. Guarini, A. Vitale, P. Fazi, M. Vignetti, A. Rambaldi, R. Foà
Format: Article
Language:English
Published: Wiley 2022-06-01
Online Access:http://journals.lww.com/10.1097/01.HS9.0000843348.46426.e0
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000843348.46426.e0

Similar Items

  • C049 | PEGASPARGASE ADMINISTRATION AND TOLERABILITY IN PATIENTS AGED 55 YEARS OR OLDER WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH THE LAL1913 PROGRAM. A SUBANALYSIS OF THE CAMPUS ALL-LAL1913 STUDY.
    by: D. Lazzarotto, et al.
    Published: (2025-09-01)
  • P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL
    by: S. Chiaretti, et al.
    Published: (2022-06-01)
  • A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
    by: Sabina Chiaretti, et al.
    Published: (2016-12-01)
  • Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
    by: Sabina Chiaretti, et al.
    Published: (2020-05-01)
  • Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
    by: Davide Lazzarotto, et al.
    Published: (2024-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs